Fei Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fei Dong has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Lynette M. Sholl
From the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Lechner, Rai, Rojas-Rudilla, Sholl, Dong)
5 shared publicationsAgoston T. Agoston
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
2 shared publicationsAmitabh Srivastava
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Now with Department of Pathology, Memorial Sloan Kettering Cancer Center, New York
2 shared publicationsChristopher D. M. Fletcher
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
2 shared publicationsCloud P. Paweletz
The Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts(Kuang, Paweletz)
2 shared publicationsDanielle K. Manning
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
2 shared publications
Latest Publications
- 30 October 2026
- Published by Wiley in Histopathology
Histological and molecular characterization of lateral extension in papillary urothelial carcinoma: implications for classification and management
Introduction: Lateral extension (LE) in urinary bladder papillary urothelial carcinoma (PUC) refers to the phenomenon where atypical urothelium is seen extending laterally in a flat configuration from the base of the papillary tumour. LE is recognized but poorly defined, resulting in inconsistent diagnoses and interpretations amongst pathologists, ranging from atypia to carcinoma in situ (CIS). Herein, we aim to better characterize LE in high‐grade PUC, utilizing en bloc transurethral resection specimens. Methods: We reviewed 37 en bloc specimens from 25 patients and performed comprehensive morphological, molecular and immunohistochemical characterization of PUC and LE components. Results: Three morphological patterns were seen: no LE ( n = 24), LE with lower‐grade cytomorphology compared to adjacent PUC (lower‐grade LE, n = 10), and LE with cytomorphology similar to adjacent PUC (higher‐grade LE, n = 3). Mean LE length was 4.7 mm (range 1.5–10.8 mm). LE extended to mucosal margins in 12/13 (92%). Differential next‐generation sequencing was performed on paired PUC and adjacent LE components in 11/13 tumours with LE. In 9/11 (82%), LE and PUC showed at least a subset of shared pathogenic/likely pathogenic alterations, supporting clonality between the two components; in five tumours, there were additional alterations specific to PUC, with and without LE‐specific alterations. Immunohistochemical staining for CK20 and p53 showed LE with abnormal CK20 in all 11/11 tumours and aberrant p53 in 3/11 (27%). PUC and LE showed concordant p53 staining patterns in 10/11 (91%) and CK20 in only 6/11 (55%) specimens. Conclusion: We find that LE can extend at least 1 cm from the base of PUC, suggesting consideration for wider resection margins if complete surgical resection is desired. Additionally, LE is clonally related to PUC in most cases, albeit with heterogeneous relationships, as evidenced by both molecular and immunohistochemical findings. Notably, LE can show immunohistochemical findings similar to those commonly reported for CIS. Recognition of LE may improve diagnostic consistency and reduce overdiagnosis of CIS in the setting of prior papillary tumours.
- 30 October 2026
- Published by Wiley in Histopathology
Histological and molecular characterization of lateral extension in papillary urothelial carcinoma: implications for classification and management
Introduction: Lateral extension (LE) in urinary bladder papillary urothelial carcinoma (PUC) refers to the phenomenon where atypical urothelium is seen extending laterally in a flat configuration from the base of the papillary tumour. LE is recognized but poorly defined, resulting in inconsistent diagnoses and interpretations amongst pathologists, ranging from atypia to carcinoma in situ (CIS). Herein, we aim to better characterize LE in high‐grade PUC, utilizing en bloc transurethral resection specimens. Methods: We reviewed 37 en bloc specimens from 25 patients and performed comprehensive morphological, molecular and immunohistochemical characterization of PUC and LE components. Results: Three morphological patterns were seen: no LE ( n = 24), LE with lower‐grade cytomorphology compared to adjacent PUC (lower‐grade LE, n = 10), and LE with cytomorphology similar to adjacent PUC (higher‐grade LE, n = 3). Mean LE length was 4.7 mm (range 1.5–10.8 mm). LE extended to mucosal margins in 12/13 (92%). Differential next‐generation sequencing was performed on paired PUC and adjacent LE components in 11/13 tumours with LE. In 9/11 (82%), LE and PUC showed at least a subset of shared pathogenic/likely pathogenic alterations, supporting clonality between the two components; in five tumours, there were additional alterations specific to PUC, with and without LE‐specific alterations. Immunohistochemical staining for CK20 and p53 showed LE with abnormal CK20 in all 11/11 tumours and aberrant p53 in 3/11 (27%). PUC and LE showed concordant p53 staining patterns in 10/11 (91%) and CK20 in only 6/11 (55%) specimens. Conclusion: We find that LE can extend at least 1 cm from the base of PUC, suggesting consideration for wider resection margins if complete surgical resection is desired. Additionally, LE is clonally related to PUC in most cases, albeit with heterogeneous relationships, as evidenced by both molecular and immunohistochemical findings. Notably, LE can show immunohistochemical findings similar to those commonly reported for CIS. Recognition of LE may improve diagnostic consistency and reduce overdiagnosis of CIS in the setting of prior papillary tumours.
- 28 October 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
Comparison of DNA- and RNA-Based Mutation Testing for Non–Small Cell Lung Cancer
- 28 October 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
Comparison of DNA- and RNA-Based Mutation Testing for Non–Small Cell Lung Cancer
- 18 October 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (1) , 22-26
Preanalytical Histology Review Improves POLE Mutation Detection in Endometrial Carcinomas
- 18 October 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (1) , 22-26
Preanalytical Histology Review Improves POLE Mutation Detection in Endometrial Carcinomas
- 4 September 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (11) , 1037-1038
Validating Fluorescence in Situ Hybridization with RNA Sequencing
- 4 September 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (11) , 1037-1038
Validating Fluorescence in Situ Hybridization with RNA Sequencing
- 29 May 2024
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 44 (2) , 325-337
Pan-Cancer Molecular Biomarkers
- 29 May 2024
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 44 (2) , 325-337
Pan-Cancer Molecular Biomarkers
- Open Access
- 28 August 2023
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 148 (5) , 553-558
Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer
Context: Droplet digital polymerase chain reaction (ddPCR) is a sensitive method to detect common pathogenic EGFR mutations in non–small cell lung cancer. Although targeted assays have not been specifically designed to detect them, uncommon EGFR mutations have been linked to response to targeted therapy. Objective: To describe atypical ddPCR patterns that correspond to uncommon but clinically actionable EGFR mutations. Design: A cohort of 1134 consecutive non–small cell lung cancers that underwent targeted next-generation sequencing was reviewed. Uncommon EGFR mutations involving probe binding sites were evaluated by ddPCR. Results: Two hundred fifty-five of 1134 cancers (22.5%) harbored pathogenic EGFR mutations. One hundred eighty-six of 255 (72.9%) had canonical EGFR exon 19 deletion or exon 21 p.L858R variants designed for detection by ddPCR. An additional 25 of 255 cases (9.8%) had uncommon EGFR mutations within the probe-binding site, including 1 case with concurrent uncommon mutations in both exon 19 and exon 21. These mutations included uncommon EGFR exon 19 deletions (n = 6), EGFR exon 19 substitutions p.L747P (n = 3) and p.L747A (n = 1), dinucleotide substitutions leading to EGFR p.L858R (n = 5), EGFR exon 21 substitutions p.K860I (n = 1) and p.L861Q (n = 9), and EGFR p.[L858R;K860I] (n = 1). Droplet digital polymerase chain reaction generated atypical but reproducible signal for each of these uncommon variants. Conclusions: Droplet digital polymerase chain reaction analysis of uncommon pathogenic EGFR variants can yield unique and reproducible results. Recognition of atypical patterns in EGFR ddPCR testing can prompt confirmatory molecular testing and aid appropriate targeted therapy selection for patients with non–small cell lung cancer.
- 28 August 2023
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 148 (5) , 553-558
Open AccessAtypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer
Context: Droplet digital polymerase chain reaction (ddPCR) is a sensitive method to detect common pathogenic EGFR mutations in non–small cell lung cancer. Although targeted assays have not been specifically designed to detect them, uncommon EGFR mutations have been linked to response to targeted therapy. Objective: To describe atypical ddPCR patterns that correspond to uncommon but clinically actionable EGFR mutations. Design: A cohort of 1134 consecutive non–small cell lung cancers that underwent targeted next-generation sequencing was reviewed. Uncommon EGFR mutations involving probe binding sites were evaluated by ddPCR. Results: Two hundred fifty-five of 1134 cancers (22.5%) harbored pathogenic EGFR mutations. One hundred eighty-six of 255 (72.9%) had canonical EGFR exon 19 deletion or exon 21 p.L858R variants designed for detection by ddPCR. An additional 25 of 255 cases (9.8%) had uncommon EGFR mutations within the probe-binding site, including 1 case with concurrent uncommon mutations in both exon 19 and exon 21. These mutations included uncommon EGFR exon 19 deletions (n = 6), EGFR exon 19 substitutions p.L747P (n = 3) and p.L747A (n = 1), dinucleotide substitutions leading to EGFR p.L858R (n = 5), EGFR exon 21 substitutions p.K860I (n = 1) and p.L861Q (n = 9), and EGFR p.[L858R;K860I] (n = 1). Droplet digital polymerase chain reaction generated atypical but reproducible signal for each of these uncommon variants. Conclusions: Droplet digital polymerase chain reaction analysis of uncommon pathogenic EGFR variants can yield unique and reproducible results. Recognition of atypical patterns in EGFR ddPCR testing can prompt confirmatory molecular testing and aid appropriate targeted therapy selection for patients with non–small cell lung cancer.
- 24 August 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (11) , 790-795
Mutational Signatures in Cancer
- 24 August 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (11) , 790-795
Mutational Signatures in Cancer
- 6 August 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (5) , 533-539
The success rates of clinical cancer next-generation sequencing based on pathologic diagnosis: Experience from a single academic laboratory
This article aims to establish the relationship between pathologic diagnosis and the rate of success in cancer next-generation sequencing testing. Clinical next-generation sequencing results performed for solid tumors were reviewed. The rate of success was analyzed in the context of tumor type and accompanying variables. Out of 683 total specimens, 533 (78.0%) underwent successful sequencing. The rate of success was 91.8% for ovarian carcinomas, 87.5% for lung non–small cell carcinomas, 82.0% for colorectal adenocarcinomas, 78.3% for melanomas, 75.9% for breast carcinomas, and 64.7% for pancreatic adenocarcinomas. For specimens that successfully underwent sequencing, pancreatic adenocarcinomas had the lowest median tumor proportion and somatic RAS and TP53 mutation allele fractions compared with other tumor types. Cytology specimens had a 33.3% success rate for pancreatic adenocarcinomas (5 of 15) and a 93.3% success rate for lung carcinomas (14 of 15). Compared with tissue from primary sites, tissue from metastatic sites showed a higher success rate for pancreatic adenocarcinomas and lower success rates for colorectal adenocarcinomas and melanomas. The success rate of cancer next-generation sequencing testing is dependent on pathologic diagnosis, tissue site, and diagnostic procedure. Understanding which specimens are at higher risk for failing molecular testing may help pathologists and clinical care teams optimize tissue acquisition and usage for patient care.
- 6 August 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (5) , 533-539
The success rates of clinical cancer next-generation sequencing based on pathologic diagnosis: Experience from a single academic laboratory
This article aims to establish the relationship between pathologic diagnosis and the rate of success in cancer next-generation sequencing testing. Clinical next-generation sequencing results performed for solid tumors were reviewed. The rate of success was analyzed in the context of tumor type and accompanying variables. Out of 683 total specimens, 533 (78.0%) underwent successful sequencing. The rate of success was 91.8% for ovarian carcinomas, 87.5% for lung non–small cell carcinomas, 82.0% for colorectal adenocarcinomas, 78.3% for melanomas, 75.9% for breast carcinomas, and 64.7% for pancreatic adenocarcinomas. For specimens that successfully underwent sequencing, pancreatic adenocarcinomas had the lowest median tumor proportion and somatic RAS and TP53 mutation allele fractions compared with other tumor types. Cytology specimens had a 33.3% success rate for pancreatic adenocarcinomas (5 of 15) and a 93.3% success rate for lung carcinomas (14 of 15). Compared with tissue from primary sites, tissue from metastatic sites showed a higher success rate for pancreatic adenocarcinomas and lower success rates for colorectal adenocarcinomas and melanomas. The success rate of cancer next-generation sequencing testing is dependent on pathologic diagnosis, tissue site, and diagnostic procedure. Understanding which specimens are at higher risk for failing molecular testing may help pathologists and clinical care teams optimize tissue acquisition and usage for patient care.
- 11 April 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 36 (6) , 100183
SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach
- 11 April 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 36 (6) , 100183
SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach
- 14 March 2023
- Published by Wiley in Histopathology
- Vol. 82 (7) , 1098-1104
Loss of functionSMAD4nonstop mutations in human cancer
Background: SMAD4is a tumour suppressor gene that is mutated in a variety of cancers.SMAD4nonstop mutations, which convert stop codons to sense codons that extend transcription, have been identified in genomic databases but have not been characterised in human pathology samples. The frequency ofSMAD4nonstop mutations and the consequences of nonstop mutations on SMAD4 protein expression are unknown.Methods: We retrospectively analysed our cancer sequencing database of 38,002 tumour specimens and evaluated the spectrum ofSMAD4mutations. SMAD4 protein expression was evaluated by immunohistochemistry in tumours withSMAD4nonstop mutations.Results: In total, 1956SMAD4mutations were identified in 1822 tumours.SMAD4mutations were most common in tumours of the gastrointestinal tract and included nonsense variants (n = 344), frameshift indels (n = 258), splice site variants (n = 104), and missense variants at codon R361 (n = 245). In a subset of cases with immunohistochemistry, SMAD4 expression was lost in 23 of 25 tumours (92%) with protein truncating variants and in 7 of 27 tumours (26%) with missense variants. Four cases harbouredSMAD4nonstop mutations.SMAD4nonstop mutations were identified in two pancreatic adenocarcinomas, one colonic adenocarcinoma, and one non‐small cell lung carcinoma. Immunohistochemistry demonstrated loss of SMAD4 protein expression in each of the four tumours withSMAD4nonstop mutations.Conclusion: SMAD4nonstop mutations are associated with loss of SMAD4 protein expression in multiple tumour types.SMAD4nonstop mutations should be clinically interpreted as pathogenic loss of function alterations when identified in cancer sequencing panels.
- 14 March 2023
- Published by Wiley in Histopathology
- Vol. 82 (7) , 1098-1104
Loss of functionSMAD4nonstop mutations in human cancer
Background: SMAD4is a tumour suppressor gene that is mutated in a variety of cancers.SMAD4nonstop mutations, which convert stop codons to sense codons that extend transcription, have been identified in genomic databases but have not been characterised in human pathology samples. The frequency ofSMAD4nonstop mutations and the consequences of nonstop mutations on SMAD4 protein expression are unknown.Methods: We retrospectively analysed our cancer sequencing database of 38,002 tumour specimens and evaluated the spectrum ofSMAD4mutations. SMAD4 protein expression was evaluated by immunohistochemistry in tumours withSMAD4nonstop mutations.Results: In total, 1956SMAD4mutations were identified in 1822 tumours.SMAD4mutations were most common in tumours of the gastrointestinal tract and included nonsense variants (n = 344), frameshift indels (n = 258), splice site variants (n = 104), and missense variants at codon R361 (n = 245). In a subset of cases with immunohistochemistry, SMAD4 expression was lost in 23 of 25 tumours (92%) with protein truncating variants and in 7 of 27 tumours (26%) with missense variants. Four cases harbouredSMAD4nonstop mutations.SMAD4nonstop mutations were identified in two pancreatic adenocarcinomas, one colonic adenocarcinoma, and one non‐small cell lung carcinoma. Immunohistochemistry demonstrated loss of SMAD4 protein expression in each of the four tumours withSMAD4nonstop mutations.Conclusion: SMAD4nonstop mutations are associated with loss of SMAD4 protein expression in multiple tumour types.SMAD4nonstop mutations should be clinically interpreted as pathogenic loss of function alterations when identified in cancer sequencing panels.